Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review (Q37633264)

21 August 2017

0 references

1 reference

title

Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review (English)

1 reference

21 August 2017

3

Marta Gwinn

1 reference

21 August 2017

4

Muin J Khoury

1 reference

21 August 2017

2

Ralph J Coates

1 reference

21 August 2017

Jun Li

1

1 reference

PubMed ID

19914946

21 August 2017

language of work or name

English

0 references

publication date

13 November 2009

1 reference

American Journal of Epidemiology

21 August 2017

1 reference

21 August 2017

171

1 reference

21 August 2017

1-13

1 reference

21 August 2017

1

1 reference

The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population

21 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Two variants on chromosome 17 confer prostate cancer risk and the one in TCF2 protects against type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Basic science aspects of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Molecular epidemiology of androgen-metabolic loci in prostate cancer: predisposition and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Molecular epidemiology of hormone-metabolic loci in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Screening for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Prevalent mutations in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Replication of the 10q11 and Xp11 prostate cancer risk variants: results from a Utah pedigree-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Power and sample size calculations. A review and computer program

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Variant in sex hormone-binding globulin gene and the risk of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Evidence for an association between the SRD5A2 (type II steroid 5 alpha-reductase) locus and prostate cancer in Italian patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

5alpha-reductase 2 polymorphisms as risk factors in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Polymorphic markers in the 5α‐reductase type II gene and the incidence of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Genotyping errors: causes, consequences and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Bayesian graphical models for genomewide association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node-positive patients following radical prostatectomy and definitive irradiation. Investigators of the National Prostate Cancer Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Preventing prostate cancer: new analyses put finasteride back on the map.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Assessment of cumulative evidence on genetic associations: interim guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

A tutorial on statistical methods for population association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Association between hormonal genetic polymorphisms and early-onset prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Low-Activity V89L Variant in SRD5A2 Is Associated with Aggressive Prostate Cancer Risk: An Explanation for the Adverse Effects Observed in Chemoprevention Trials Using 5-Alpha-Reductase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Evaluation of Genetic Variations in the Androgen and Estrogen Metabolic Pathways as Risk Factors for Sporadic and Familial Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

Germ-Line Genetic Variation in the Key Androgen-Regulating Genes Androgen Receptor, Cytochrome P450, and Steroid-5- -Reductase Type 2 Is Important for Prostate Cancer Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWP318

21 January 2018

Identifiers

DOI

10.1093/AJE/KWP318

1 reference

21 August 2017

1 reference

PubMed ID

19914946